Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

April 23, 2026 updated by: St. Jude Children's Research Hospital

This study will treat participants with newly diagnosed, low, intermediate and high risk rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic chemotherapy.

PRIMARY OBJECTIVE:

  • Estimate event-free survival for intermediate risk participants treated with vincristine, dactinomycin and cyclophosphamide with the addition of maintenance anti-angiogenic therapy.

SECONDARY OBJECTIVES:

  • Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
  • Maintain a high local control rate in participants treated with surgery and/or limited volume proton and photon radiation without dose escalation.
  • Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume.
  • Establish the feasibility of delivering 4 cycles of maintenance anti-angiogenic chemotherapy in intermediate and high risk patients following standard chemotherapy.
  • Estimate the event free survival for high risk patients receiving interval dose compressed therapy and maintenance anti-angiogenic therapy.
  • Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Participants will be stratified based on both a pretreatment staging system and a post-surgery surgico/pathologic clinical grouping system. Treatment for low-risk (subset 1) participants will consist of chemotherapy and radiation. Low-risk (subset 2) and intermediate-risk participants will receive chemotherapy and radiation and/or undergo surgery to destroy/remove the tumor. Intermediate-risk participants will also receive 16 weeks of maintenance chemotherapy. High-risk participants will receive chemotherapy and radiation therapy. High-risk participants will also receive additional maintenance therapy with anti-angiogenic chemotherapy.

Study Type

Interventional

Enrollment (Actual)

115

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Jacksonville, Florida, United States, 32207
        • Nemours Children's Clinic
      • Jacksonville, Florida, United States, 32206
        • University of Florida Proton Therapy Institute
    • Tennessee
      • Memphis, Tennessee, United States, 38105
        • St. Jude Children's Research Hospital
    • Texas
      • Fort Worth, Texas, United States, 76104
        • Cook Children's Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 21 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Newly diagnosed participants with localized rhabdomyosarcoma (RMS).

  • Must have either low-, intermediate-, or high-risk disease, defined as:

    • Low-risk: Embryonal, botryoid, spindle cell tumors only (Subset 1: Stage 1, Group I; Stage 1 Group I; Stage 1 Group III orbital only; Stage 2 Group I; Stage 2 Group II) (Subset 2: Stage 1 Group III non orbit; Stage 3 Group I, II)
    • Intermediate-risk: Embryonal, botryoid, or spindle cell RMS Stage 2 or 3 and Group III; Alveolar, undifferentiated, or anaplastic RMS: Stage 1-3, group I-I; I)
    • High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with metastatic disease at diagnosis (stage 4).
    • Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol.
  • Age < 22 years (eligible until 22nd birthday)
  • Performance level corresponding to ECOG score of 0, 1, or 2. The Lansky performance score should be used for participants < 16 years
  • Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding steroids) unless an emergency situation requires local tumor treatment. Prior biopsy, surgical resection and lymph node sampling is allowed.
  • Initiation of chemotherapy is planned within 6 weeks (42 days) of the definitive biopsy or surgical resection.

  • Adequate bone marrow function defined as:

    • Peripheral absolute neutrophil count (ANC) ≥ 750/μL
    • Platelet count ≥ 75,000/μL (transfusion independent)
  • Adequate liver function defined as total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age. Participants with biliary or hepatic primaries with bilirubin values greater than 1.5 x ULN may be enrolled on study if all other eligibility criteria are met.

  • Adequate renal function defined as:

    • Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.732 or
    • Serum creatinine based on age and gender
    • Participants with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract.
  • Patients requiring emergency radiation therapy are eligible for enrollment on this study.
  • Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants ≥ 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment. Female participants who are breast feeding must agree to stop breast feeding.
  • Sexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least 1 month after treatment is completed.
  • No evidence of active, uncontrolled infection.
  • All participants and/or their parents or legal guardians must sign a written informed consent.

Exclusion Criteria:

  • Participants who fail to meet one or more of the inclusion criteria will be excluded.

Inclusion Criteria for Contrast-Enhanced Ultrasound (CEUS) Sub-Study:

  • Newly diagnosis or suspected diagnosis of previously untreated participants with rhabdomyosarcoma (RMS). NOTE: Patients with suspected diagnosis of RMS may enroll on screening part of study but must have histologic diagnosis to enroll on treatment part of study.
  • Must have either intermediate-risk or high risk disease.
  • 0-21 years of age.

Exclusion Criterial for CEUS Sub-Study:

  • Undergoing upfront surgical resection of the primary tumor.
  • History of allergy to Optison(TM) contrast agent or blood products.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low-Risk, Subset 1

Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.

Participants also receive ^1^1C-methionine as described in the intervention section.
Drug: Vincristine

Dosage and route of administration:

  • < 1 year of age=0.025 mg/kg intravenously (IV)
  • > 1 year and < 3 years= 0.05 mg/kg IV
  • ≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants.
Other Names:
  • Oncovin®
Drug: Dactinomycin

Dosage and route of administration:

  • < 1 year=0.025 mg/kg IV push
  • ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
Other Names:
  • Actinomycin-D
  • Cosmegen®
Drug: Cyclophosphamide

Dosage and route of administration:

During VAC chemotherapy:

  • < 3 years of age = 40 mg/kg IV
  • ≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.

During maintenance for intermediate-risk participants:

  • oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)
Other Names:
  • Cytoxan(R)
Procedure: Surgical Resection
Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
Other Names:
  • Surgery
Procedure: Radiation
Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
Other Names:
  • External Beam Radiation
  • Brachytherapy
  • Proton Beam Radiation
Drug: Myeloid Growth Factor

If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.

High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Other Names:
  • Filgrastim
  • G-CSF
  • Pegfilgrastim
Procedure: Lymph Node Sampling
Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.
Drug: ^1^1C-methionine
Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Other Names:
  • Contrast Media
Experimental: Low-Risk, Subset 2

Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.

Participants also receive ^1^1C-methionine as described in the intervention section.
Drug: Vincristine

Dosage and route of administration:

  • < 1 year of age=0.025 mg/kg intravenously (IV)
  • > 1 year and < 3 years= 0.05 mg/kg IV
  • ≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants.
Other Names:
  • Oncovin®
Drug: Dactinomycin

Dosage and route of administration:

  • < 1 year=0.025 mg/kg IV push
  • ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
Other Names:
  • Actinomycin-D
  • Cosmegen®
Drug: Cyclophosphamide

Dosage and route of administration:

During VAC chemotherapy:

  • < 3 years of age = 40 mg/kg IV
  • ≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.

During maintenance for intermediate-risk participants:

  • oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)
Other Names:
  • Cytoxan(R)
Procedure: Radiation
Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
Other Names:
  • External Beam Radiation
  • Brachytherapy
  • Proton Beam Radiation
Drug: Myeloid Growth Factor

If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.

High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Other Names:
  • Filgrastim
  • G-CSF
  • Pegfilgrastim
Procedure: Lymph Node Sampling
Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.
Drug: ^1^1C-methionine
Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Other Names:
  • Contrast Media
Experimental: Intermediate-Risk

Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.

Participants also receive ^1^1C-methionine as described in the intervention section.
Drug: Vincristine

Dosage and route of administration:

  • < 1 year of age=0.025 mg/kg intravenously (IV)
  • > 1 year and < 3 years= 0.05 mg/kg IV
  • ≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants.
Other Names:
  • Oncovin®
Drug: Dactinomycin

Dosage and route of administration:

  • < 1 year=0.025 mg/kg IV push
  • ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
Other Names:
  • Actinomycin-D
  • Cosmegen®
Drug: Cyclophosphamide

Dosage and route of administration:

During VAC chemotherapy:

  • < 3 years of age = 40 mg/kg IV
  • ≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.

During maintenance for intermediate-risk participants:

  • oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)
Other Names:
  • Cytoxan(R)
Procedure: Surgical Resection
Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
Other Names:
  • Surgery
Procedure: Radiation
Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
Other Names:
  • External Beam Radiation
  • Brachytherapy
  • Proton Beam Radiation
Drug: Myeloid Growth Factor

If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.

High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Other Names:
  • Filgrastim
  • G-CSF
  • Pegfilgrastim
Procedure: Lymph Node Sampling
Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.
Drug: ^1^1C-methionine
Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Other Names:
  • Contrast Media
Drug: Bevacizumab
Dosage and route of administration: 15 mg/kg/dose/day IV.
Other Names:
  • Avastin®
  • VEGF
  • rhuMab
Drug: Sorafenib
Dosage and route of administration: 90 mg/m^2/dose twice daily.
Other Names:
  • Nexavar®
Experimental: High-Risk

Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.

Participants also receive ^1^1C-methionine as described in the intervention section.
Drug: Vincristine

Dosage and route of administration:

  • < 1 year of age=0.025 mg/kg intravenously (IV)
  • > 1 year and < 3 years= 0.05 mg/kg IV
  • ≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants.
Other Names:
  • Oncovin®
Drug: Dactinomycin

Dosage and route of administration:

  • < 1 year=0.025 mg/kg IV push
  • ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
Other Names:
  • Actinomycin-D
  • Cosmegen®
Drug: Cyclophosphamide

Dosage and route of administration:

During VAC chemotherapy:

  • < 3 years of age = 40 mg/kg IV
  • ≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.

During maintenance for intermediate-risk participants:

  • oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)
Other Names:
  • Cytoxan(R)
Procedure: Surgical Resection
Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
Other Names:
  • Surgery
Procedure: Radiation
Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
Other Names:
  • External Beam Radiation
  • Brachytherapy
  • Proton Beam Radiation
Drug: Myeloid Growth Factor

If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.

High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Other Names:
  • Filgrastim
  • G-CSF
  • Pegfilgrastim
Procedure: Lymph Node Sampling
Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.
Drug: ^1^1C-methionine
Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Other Names:
  • Contrast Media
Drug: Bevacizumab
Dosage and route of administration: 15 mg/kg/dose/day IV.
Other Names:
  • Avastin®
  • VEGF
  • rhuMab
Drug: Sorafenib
Dosage and route of administration: 90 mg/m^2/dose twice daily.
Other Names:
  • Nexavar®
Drug: Irinotecan
Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m^2 IV (maximum dose 100 mg/day) daily x 5.
Other Names:
  • Camptosar ®
Drug: Ifosfamide
Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m^2/day IV x 5 Age <1 year: treat with 50% doses calculated on a m^2 basis.
Other Names:
  • Ifex ®
Drug: Etoposide

Dosage and Route of Administration:

Age >1 year 100 mg/m^2/day IV x 5 Age < 1 year treat with 50% doses calculated on a m^2 basis

Other Names:
  • VP-16
  • Vepesid®
Drug: Etoposide Phosphate
Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m^2/day IV.
Other Names:
  • Etopophos®
Drug: Doxorubicin

Dosage and route of Administration:

Age ≥1 year, 37.5 mg/m^2 IV over 1 hour x 2 days Age <1 year, 18.75 mg/m^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.

Other Names:
  • Adriamycin®
Drug: Dexrazoxane

Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.

Age ≥1 year, 375 mg/m^2 IV over 15-30 minutes Age <1 year, 187l.5 mg/m^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.

Other Names:
  • Zinecard

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Event-free survival (intermediate risk arm)
Time Frame: 2 years after last intermediate risk arm enrollment
To estimate event-free survival for intermediate risk participants treated by vincristine-dactinomycin-cyclophosphamide (VAC) with the addition of maintenance anti-angiogenic therapy
2 years after last intermediate risk arm enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Event-free survival (high risk arm)
Time Frame: 5 years after last high-risk arm enrollment
To estimate event-free survival for high risk participants.
5 years after last high-risk arm enrollment
Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms)
Time Frame: 2 years after last low or intermediate arm enrollment
Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
2 years after last low or intermediate arm enrollment
Rate of false negative and false positive the sentinel lymph node procedure (high risk arm)
Time Frame: 5 years after last high risk arm enrollment
Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
5 years after last high risk arm enrollment
Local failure rate (low and intermediate risk arms)
Time Frame: 2 years after last low or intermediate risk arm enrollment
Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation
2 years after last low or intermediate risk arm enrollment
Local failure rate (high risk arm)
Time Frame: 5 years after last high risk arm enrollment
Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation
5 years after last high risk arm enrollment
Patterns of failure (low and intermediate risk arms)
Time Frame: 2 years after last low or intermediate risk arm enrollment
Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume
2 years after last low or intermediate risk arm enrollment
Patterns of failure (high risk arm)
Time Frame: 5 years after last high risk arm enrollment
Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume
5 years after last high risk arm enrollment
Number of patients that complete all cycles of maintenance chemotherapy (intermediate risk arm)
Time Frame: 2 years after last low or intermediate risk arm enrollment
Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in intermediate risk patients following standard chemotherapy.
2 years after last low or intermediate risk arm enrollment
Number of patients that complete all cycles of maintenance chemotherapy (high risk arm)
Time Frame: 5 years after last high risk arm enrollment
Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in high risk patients following standard chemotherapy.
5 years after last high risk arm enrollment
Incidence of CTC grade 3 and higher toxicities related to proton bream therapy (low and intermediate and high risk arms)
Time Frame: 2 years after last enrollment
Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.
2 years after last enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Jude Children's Research Hospital

Investigators

  • Principal Investigator: Matthew J. Krasin, MD, St. Jude Children's Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 4, 2013

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

June 1, 2030

Study Registration Dates

First Submitted

May 30, 2013

First Submitted That Met QC Criteria

June 4, 2013

First Posted (Estimated)

June 7, 2013

Study Record Updates

Last Update Posted (Actual)

April 24, 2026

Last Update Submitted That Met QC Criteria

April 23, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RMS13
  • NCI-2013-00913 (Registry Identifier: NCI Clinical Trial Registration Program)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rhabdomyosarcoma

Clinical Trials on Vincristine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe